<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFE5C6FD-3500-44F6-B100-184B5F2FD0D7"><gtr:id>AFE5C6FD-3500-44F6-B100-184B5F2FD0D7</gtr:id><gtr:name>Microsoft Research</gtr:name><gtr:address><gtr:line1>One Microsoft Way</gtr:line1><gtr:line4>Redmond</gtr:line4><gtr:line5>Washington 98052</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFE5C6FD-3500-44F6-B100-184B5F2FD0D7"><gtr:id>AFE5C6FD-3500-44F6-B100-184B5F2FD0D7</gtr:id><gtr:name>Microsoft Research</gtr:name><gtr:address><gtr:line1>One Microsoft Way</gtr:line1><gtr:line4>Redmond</gtr:line4><gtr:line5>Washington 98052</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/687EF383-45F5-40F7-BE5A-48959DD53EBB"><gtr:id>687EF383-45F5-40F7-BE5A-48959DD53EBB</gtr:id><gtr:firstName>Philippa</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Matthews</gtr:surname><gtr:orcidId>0000-0002-4036-4269</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501777"><gtr:id>709EEE36-A75A-4B01-8CAD-DC62ADFBEAD8</gtr:id><gtr:title>Viral attenuation driven by Cytotoxic T Lymphocyte escape</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0501777</gtr:grantReference><gtr:abstractText>HIV infection may be quiescent for months to years, but ultimately overwhelms the immune system rendering the individual susceptible to life-threatening infection. Initially, the host immune system controls HIV infection by mounting a white cell (cytotoxic T lymphocyte, CTL) response against proteins expressed by the virus. HIV evades the CTL response by mutation of these proteins, presenting a major challenge to immune or vaccine-mediated control.

A large cohort of HIV infected individuals from Durban has previously been studied, in whom viral sequencing has defined specific mutations which allow the virus to escape from the host CTL response. Our specific aims are to characterise in more detail the HIV protein sequences in which mutations occur, to define whether these mutations persist following transmission, to establish the structural consequences of mutations, and to identify ways in which the virus compensates for the deleterious effects of mutations. 

Enhancing our understanding of these areas provides insight into the mechanism by which HIV evades CTL control. In the long-term, this contributes to designing vaccines which prime the host immune system, facilitating improved control of infection</gtr:abstractText><gtr:technicalSummary>Background: A major obstacle to successful immune control of HIV is viral mutation and escape from cytotoxic T lymphocyte (CTL) recognition. However, recent data indicate that escape mutation from CTL can result in significant cost to viral replicative capacity. The CTL responses so far identified capable of attenuating HIV via CTL escape are associated with successful control of viraemia. The overall goal of this project is therefore to characterise in detail these key CTL responses, since they may play a critical role in immune control of HIV. Detailed knowledge of the specific vulnerabilities of the virus that are susceptible to immune attack will be of considerable significance to vaccine design.

Specific aims and objectives: The specific aims of the proposed studies are to perform a detailed
analysis of HIV-specific CTL epitopes at which escape and reversion occur:
1. To characterise the escape options from key CTL responses and to identify potential compensatory mutations available to the virus; 
2. To assess the impact of these mutations on CTL recognition; 
3. To characterize the functional significance of escape and compensatory mutants, including their impact on in vitro viral fitness, and their structural consequences.

Methodology:
The study cohort includes &amp;gt;1500 C-clade infected, treatment-naive study subjects who are either enrolled in Durban, South Africa or in UK GU clinics. 5 new reverting epitopes have already been identified by Dr Goulder?s group; all lie within capsid, RT and integrase, the most conserved HIV proteins. These and additional reverting epitopes will be the focus of these studies. Additional sequencing of the relevant region of HIV encoding the epitope(s) of interest, and of study subjects expressing the relevant HLA allele will be undertaken to define the escape and compensatory option at these key epitopes. CTL assays will be employed to determine the impact of these mutations identified on CTL recognition. In vitro vir fitness assays will determine whether particular mutations exact a fitness cost, and to what extent potential compensatory mutations restore that fitness cost. Structural analysis of these mutants using published structures for capsid, RT and integrase will indicate functional constraints operating against escape within these epitopes.

Scientific and medical opportunities of the study:
Collaboration with local and international groups, both clinical and scientific, on a major global health problem such as HIV, will provide excellent opportunities for the candidate to develop as a clinician-scientist and make a substantial contribution towards an effective CTL-based HIV vaccine.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>165406</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Microsoft Research</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Microsoft data analysis</gtr:description><gtr:id>BBD472F3-E3B2-44B0-90BD-F9BD264A1D4F</gtr:id><gtr:impact>Generation of multiple publications, e.g. see PMID 24501417, 24023819, 23094091, 22973023, 21498667, 21106744, 20660184, 19244334, 19023406, 18434400, 18426987</gtr:impact><gtr:outcomeId>546479f94f7148.05391142-1</gtr:outcomeId><gtr:partnerContribution>Designing and implementing software packages for analysis of large genomic databases.</gtr:partnerContribution><gtr:piContribution>Collection and generation of raw data, and hypothesis generation for data analysis. Feedback to develop and improve software algorithms for data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Keystone HIV Conference: Poster Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>292A9D6C-AEC8-420F-A470-4532419F4EDB</gtr:id><gtr:impact>Keystone HIV Conference; Whistler, Canada; 2007. Poster entitled 'Unexpected high frequency of reversion in Nef escape mutations in HIV-1'.

Stimulated expert discussion; opportunity for liaison with collaborators from USA and Australia.
Ongoing research into this area has ultimately led to a published paper on which I am senior author (Adland et al, PLoS One. 2013 Sep 2;8(9):e73117).</gtr:impact><gtr:outcomeId>pd3s21rWoqe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.keystonesymposia.org</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Infection Society Annual Meeting 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>90FC8219-B12C-4F32-ACCC-8D25B1338ED3</gtr:id><gtr:impact>British Infection Society Annual Meeting, London, May 2011. Oral presentation of research to a large national meeting of Infectious Diseases and Microbiology clinicians.
Talk entitled: 'New Insights into HLA in control of HIV: how viraemic suppression adds up'


Stimulated expert discussion.</gtr:impact><gtr:outcomeId>ozYTWSfYvJN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.britishinfection.org/drupal/</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Audit, revision of clinical guidelines, and presentation to clinical and pharmacy teams: use of oral fosfomycin</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D652FCD7-3E8A-42B2-8520-343B599786E7</gtr:id><gtr:impact>I led an audit into the local use of oral fosfomycin to treat urinary tract infections. This culminated in the presentation of data to the local antimicrobial steering group, and to the 'OXMID' clinical group (Oxford Microbiology and Infectious Diseases, which including clincians, biomedical scientists, pharmacists and undergraduate students). The recommendations have been added to the local antimicrobial formulary ('Microguide') and have been written up as a manuscript (currently in review with Journal of Infection).

Prompted further interest from medical colleagues in the field of HIV vaccine design, and led to opportunities for repeat talks in following years.</gtr:impact><gtr:outcomeId>aZZUMnbZGvM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster presentation at HBV International Conference, Seoul, South Korea, Sept 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>14041590-5BBD-4FCF-88EF-122EA388FD25</gtr:id><gtr:impact>I attended the international HBV Meeting in Seoul, South Korea. I presented a poster showcasing my work to collate all known HBV epitopes. This led to interesting and constructive dialogue with established collaborators as well as allowing me to make new links.</gtr:impact><gtr:outcomeId>58926e66035de9.80641410</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://f1000research.com/posters/5-2357</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Infection Society Annual Meeting 2009</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1835AE33-2DD6-4F5B-8F74-63DAD24E12CD</gtr:id><gtr:impact>British Infection Society Annual Meeting, London, May 2009. Oral presentation of research to a large national meeting of Infectious Diseases and Microbiology clinicians.
Talk entitled: 'Inter-Continental patterns of HIV-1 control: HLA and the quest for a T cell vaccine'
Abstract published here: J Infection 01/2009; 59(6). DOI:10.1016/j.jinf.2009.10.012

Positive feedback from a diverse audience; interesting discussions with experts in the field following the talk.</gtr:impact><gtr:outcomeId>tjYGeLiPskQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.britishinfection.org/drupal/</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article feature in World Biomedical Frontiers</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>54410785-A363-4796-8A8B-4F931E329EBE</gtr:id><gtr:impact>On-line open access summary of recently published work to stimulate further interest and reach a wider audience - both of science professionals and the wider public. (Original reference Matthews et al PLoS One. 2012;7(10):e47799.)

Only recently went live; no tangible impacts to date.</gtr:impact><gtr:outcomeId>ND1mxivPZMA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://biomedfrontiers.org/infection-2013-12-23/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Federation of Infection Societies Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>32F2682D-C759-470C-B68E-F97AF39CD642</gtr:id><gtr:impact>Federation of Infection Societies (FIS) UK Meeting; Cardiff, Wales; November 2007. Presentation to a large audience of Infectious Diseases and Microbiology experts in attendance at an annual national meeting. Talk entitled 'Convergent evolution in HIV-1 mediated by HLA selection'.

Awarded prize for best research presentation.</gtr:impact><gtr:outcomeId>CmpCX1PkdWZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www-07.all-portland.net/meetings/pdfabstracts/FIS2007.pdf</gtr:url><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AIDS Vaccine Conference: Poster Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2CC35F85-A39A-45A0-8783-B3BB563DF137</gtr:id><gtr:impact>AIDS Vaccine Conference; Cape Town, South Africa; October 2008. This poster was selected as being of special interest and allocated a slot for oral presentation to an international audience of clinicians, academics and scientists in the field of HIV Vaccinology.

Stimulated interesting debate among an expert audience. Generated interest in our poster presentation and subsequent paper (Matthews et al, J Virol. 2009;83(9):4605-15).</gtr:impact><gtr:outcomeId>nXnuXcqxLxC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.vaccineenterprise.org/conference_archive/2008/index.html</gtr:url><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster/presentation at CROI meeting, Seattle, Feb 2017</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E160581D-4BF1-4A96-A595-33B0C2EFA1B9</gtr:id><gtr:impact>A post-doc representing HIV work that I have contributed to under the supervision of Prof Philip Goulder won a travel scholarship to attend the CROI meeting in Seattle to present our work.

Abstract #799
Poster title: Rapid Restoration of Effective anti-HIV CD4+ T-Cell Activity in ART-Treated Children
Authors: Emily Adland, Luisa Mori, Leana Laker, Alice Swordy, Anna Csala, Masahiko Mori, Philippa Matthews, Pieter Jooste, Philip Goulder</gtr:impact><gtr:outcomeId>58aac099413b83.78263683</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.croiconference.org/sessions/rapid-restoration-effective-anti-hiv-cd4-t-cell-activity-art-treated-children</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7316</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Fund Bridging Grant</gtr:description><gtr:end>2009-11-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>BEBFA1F0-879A-413F-9BB3-6D8D34209829</gtr:id><gtr:outcomeId>546495d1dd1a87.03345529</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1115791</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Intermediate Clinical Fellowship</gtr:description><gtr:end>2021-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3127D8B5-E163-47F4-95F0-63BB0DCBFA88</gtr:id><gtr:outcomeId>56d55850a51714.47150737</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B7133FA7-94C7-4355-BDC5-62A555BF06AE</gtr:id><gtr:title>P16-07. HLA-B1302 is associated with viral control in clade CRF01_AE HIV-1 infection in Thailand</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb8509f8416b01120ce1cfccb16160b6"><gtr:id>bb8509f8416b01120ce1cfccb16160b6</gtr:id><gtr:otherNames>Hempel U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>doi_15698__6_S3_P236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD54D689-BB21-41F2-9473-6C8C6F778E9E</gtr:id><gtr:title>P07-09. Contemporaneous transmission of genetically distinct HIV variants from a single donor to two recipients</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d3d35d367a42471775bc621386670a1"><gtr:id>1d3d35d367a42471775bc621386670a1</gtr:id><gtr:otherNames>English S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>doi-15698-10_1186_1742_4690_6_S3_P107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB44096C-C126-4964-887D-E22E92944060</gtr:id><gtr:title>HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58925f0ae8f443.23068970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F34F6DA6-CCD9-4E7F-BAFE-B5130FD8D2F5</gtr:id><gtr:title>Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1953a422ebdfeba27e3243d46dc23c08"><gtr:id>1953a422ebdfeba27e3243d46dc23c08</gtr:id><gtr:otherNames>Leitman EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56e941728a3c36.99434806</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A74995C5-FA12-409A-9C4D-5242AFA8AB00</gtr:id><gtr:title>HLA-mediated control of HIV and HIV adaptation to HLA.</gtr:title><gtr:parentPublicationTitle>Advances in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cc35c67f1f89bfab8c3f77b00113a5"><gtr:id>17cc35c67f1f89bfab8c3f77b00113a5</gtr:id><gtr:otherNames>Payne RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0065-308X</gtr:issn><gtr:outcomeId>58925f0b5aa211.10039175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A32E9C48-0BFE-4306-B29C-EF7DE3502BA7</gtr:id><gtr:title>Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fd3d6b237a769e709489e85aafbce8f"><gtr:id>5fd3d6b237a769e709489e85aafbce8f</gtr:id><gtr:otherNames>Payne R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5464944c427741.30175746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CDD1AA1-FE23-44C9-8A22-A5D42AA6537E</gtr:id><gtr:title>HLA Footprints on Human Immunodeficiency Virus Type 1 Are Associated with Interclade Polymorphisms and Intraclade Phylogenetic Clustering</gtr:title><gtr:parentPublicationTitle>Journal of Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e647c6042eda2f8484f124984a799a3"><gtr:id>0e647c6042eda2f8484f124984a799a3</gtr:id><gtr:otherNames>Matthews P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>58925f0acb6713.72086062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56534CC4-6D04-4CFF-82D0-3AF744A098CC</gtr:id><gtr:title>The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da830d5dc96d2a04bf13f5cd6fff4caa"><gtr:id>da830d5dc96d2a04bf13f5cd6fff4caa</gtr:id><gtr:otherNames>Crawford H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15698_28_21106744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3391005-976D-48AD-AD90-42D0229FE993</gtr:id><gtr:title>P16-04. Cryptic CTL epitopes derived from antisense transcription are frequently recognized in HIV-1 infection</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/332aa3c174d2264869cd14658555203a"><gtr:id>332aa3c174d2264869cd14658555203a</gtr:id><gtr:otherNames>Bansal A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>doi_15698__6_S3_P233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8D71437-AE14-47CC-8347-CC91C1C301C0</gtr:id><gtr:title>Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071aa867a6d96e08f6398d3074b97da1"><gtr:id>071aa867a6d96e08f6398d3074b97da1</gtr:id><gtr:otherNames>Goepfert PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>58925f0b945559.63031675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99607A62-405E-4212-8F62-CFE04B2AFC92</gtr:id><gtr:title>Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58925f0b78dad1.06239319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A77BB55B-39CB-496F-ABF5-07DB322C1196</gtr:id><gtr:title>Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e71e435ee193f5c5787b32226caf7061"><gtr:id>e71e435ee193f5c5787b32226caf7061</gtr:id><gtr:otherNames>Mori M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>565ddf5e8cf8e0.72789787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>923614FA-9B1F-4AC2-9E8E-243872BCEC4C</gtr:id><gtr:title>Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17cc35c67f1f89bfab8c3f77b00113a5"><gtr:id>17cc35c67f1f89bfab8c3f77b00113a5</gtr:id><gtr:otherNames>Payne RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>56d556e7e4c263.33914625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4CA50CA-DB4C-4E20-97F1-7A3958CD581F</gtr:id><gtr:title>Subdominant Gag-specific anti-HIV efficacy in an HLA-B*57-positive elite controller.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1953a422ebdfeba27e3243d46dc23c08"><gtr:id>1953a422ebdfeba27e3243d46dc23c08</gtr:id><gtr:otherNames>Leitman EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56e94172677a63.00246453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED07FF4C-BC79-4332-9097-2578EFFFDC13</gtr:id><gtr:title>Defining Efficacious HIV-Specific Cytotoxic T Lymphocyte Responses Using Saporin-Conjugated Peptide-MHC Tetramers</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e327433f9dcbc7fd0ed58edffb1c727e"><gtr:id>e327433f9dcbc7fd0ed58edffb1c727e</gtr:id><gtr:otherNames>Leitman, EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5464879d2b70c9.52994591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41916173-7AD2-40C1-9234-14041A949D8B</gtr:id><gtr:title>Disease progression despite protective HLA expression in an HIV-infected transmission pair.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/283304db75ef6c394048c146bbf4303c"><gtr:id>283304db75ef6c394048c146bbf4303c</gtr:id><gtr:otherNames>Brener J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn><gtr:outcomeId>565ddf5e69bf84.85148350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF62E90A-4CE5-4B6B-9909-AE32FEF6A02B</gtr:id><gtr:title>HIV subtype influences HLA-B*07:02-associated HIV disease outcome.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5c2d35d76a3ff3436246776122a7aa9"><gtr:id>f5c2d35d76a3ff3436246776122a7aa9</gtr:id><gtr:otherNames>Kl?verpris HN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn><gtr:outcomeId>pm_15698_28_24010680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5137772-4499-4F88-A1E1-395363707DC9</gtr:id><gtr:title>Additive contribution of HLA class I alleles in the immune control of HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38fbfa37bb1008fe3395f2c7fe0b9417"><gtr:id>38fbfa37bb1008fe3395f2c7fe0b9417</gtr:id><gtr:otherNames>Leslie A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15698_28_20660184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E097AC2-DFE1-458E-976B-DEDFD459D4CF</gtr:id><gtr:title>HLA footprints on human immunodeficiency virus type 1 are associated with interclade polymorphisms and intraclade phylogenetic clustering.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58925f0b16c119.20440974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A35BF9C1-E566-47C1-8137-BE37921084AE</gtr:id><gtr:title>Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8abfef0b8fb012b72db3d9f0eef2018"><gtr:id>f8abfef0b8fb012b72db3d9f0eef2018</gtr:id><gtr:otherNames>Martinez-Picado J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15698_18_16537629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C290CF5A-7537-4E5B-BC29-D4464336A794</gtr:id><gtr:title>Differential clade-specific HLA-B*3501 association with HIV-1 disease outcome is linked to immunogenicity of a single Gag epitope.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fb25d83715c29e0eaf7b3a566c436ba"><gtr:id>0fb25d83715c29e0eaf7b3a566c436ba</gtr:id><gtr:otherNames>Matthews PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15698_28_22973023</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBC771F6-18CB-43A9-B373-C90785EC0739</gtr:id><gtr:title>Nef-specific CD8+ T cell responses contribute to HIV-1 immune control.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81959f2a0b1cc2014169164ebdc5f383"><gtr:id>81959f2a0b1cc2014169164ebdc5f383</gtr:id><gtr:otherNames>Adland E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15698_28_24023819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9100EA3B-1B91-45AD-A19B-D42520CFD3F2</gtr:id><gtr:title>Adaptation of HIV-1 to human leukocyte antigen class I.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99f9638246ae93c3412e8a61dc7cec4"><gtr:id>d99f9638246ae93c3412e8a61dc7cec4</gtr:id><gtr:otherNames>Kawashima Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58925f0b37eea0.43982061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D3F6F2-1EA7-4FE7-A80D-189229B12CC8</gtr:id><gtr:title>Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/341e8375fd0b70edf6a5b6519cee6d87"><gtr:id>341e8375fd0b70edf6a5b6519cee6d87</gtr:id><gtr:otherNames>Carlson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>doi_15698_bi_1000225</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501777</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>